MedTrace Logo

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

NCT02491684 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2019-02-12

Study results available
· View outcomes & findings →

Summary

A study to investigate if inhaled Interferon beta-1a is safe and tolerated, and can prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of symptoms of common cold or influenza

Conditions

Interventions

DRUG

Interferon beta-1a Nebuliser solution 48 μg/mL

Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days

DRUG

Placebo

Placebo solution for once daily inhalation for 14 days

Sponsors & Collaborators

Principal Investigators

  • Per Gustafson, MD PhD · AstraZeneca, R&D mölndal

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-21
Primary Completion
2016-11-24
Completion
2016-11-24

Countries

  • Argentina
  • Australia
  • Colombia
  • France
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02491684 on ClinicalTrials.gov